UroGen Q4 2021 Earnings Report
Key Takeaways
UroGen Pharma reported a net product revenue of $16.2 million for Q4 2021 from Jelmyto, representing a 42% increase over the previous quarter. The company also announced an up to $100 million senior secured term loan facility to support operations to reach cash flow breakeven by 2025.
Jelmyto net product revenue increased 42% over Q3 2021, reaching $16.2 million in Q4 2021.
Full-year net product revenue of $48.0 million was in line with guidance.
UroGen announced up to $100 million senior secured term loan facility with Pharmakon Advisors, expected to support operations to reach cash flow breakeven by 2025.
The first patient was dosed in ENVISION, a single-arm Phase 3 pivotal study for UGN-102 in bladder cancer.
UroGen
UroGen
UroGen Revenue by Segment
Forward Guidance
The Company anticipates full year 2022 net product revenues from Jelmyto to be in the range of $70 to $80 million. The Company anticipates full year 2022 operating expenses in the range of $140 to $160 million, including non-cash share-based compensation expense of $10 to $16 million, subject to market conditions. The Company anticipates full year 2022 financing expense related to the prepaid obligation to RTW Investments in the range of $22 to $26 million, of which approximately $9.1 to $10.4 million will be in cash.
Positive Outlook
- Full year 2022 net product revenues from Jelmyto to be in the range of $70 to $80 million.
- Operating expenses are anticipated to be in the range of $140 to $160 million.
- Non-cash share-based compensation expense of $10 to $16 million is expected.
- Financing expense related to the prepaid obligation to RTW Investments in the range of $22 to $26 million is anticipated.
- Approximately $9.1 to $10.4 million will be in cash.